Originally Aired - Wednesday, March 13 • 2:30 PM - 3:30 PM Eastern Time (US & Canada)
Create or Log in to My Show Planner to see Videos and Resources.
Create or Login to MyHIMSSPlanner to build your schedule and see more information.
{{chatBodyContent}}
Be sure to come back after the session starts to have access to session resources.
Location: W308A
Type: General Education
Session ID: 156
Title: Combatting Counterfeit Drugs and the Drug Supply Chain Security Act
Description: Counterfeit drugs found in the healthcare supply chain are rising and pose a significant risk to patient safety. Those containing no active ingredients may be just as dangerous as those containing contaminants. At best, such medications do not treat the ailments they purport to treat. At worse, they contain toxic ingredients that can kill patients. Healthcare executives need a cohesive strategy to monitor the pharmaceutical supply chain from manufacturing all the way to patient administration. This session will explore the FDA’s Drug Supply Chain Security Act (DSCSA) that recently went into effect, and how current and emerging technologies are addressing pain points throughout the entire supply chain. Attendees will learn about the findings of an end-to-end pharmaceutical supply chain pilot study conducted by The Axia Institute, that included 16 industry participants across major pharmaceutical manufacturers, wholesalers, dispensers and technology providers. The study examined the technical viability and value proposition of leveraging automated tracking systems to combat counterfeit drugs in support of the DSCSA legislation. We will explore the adoption of new safety techniques implemented all the way from pharmaceutical manufacturing to the patient to help ensure safe medication is available and administered to patients in general and critical care areas.
Level: Intermediate
Format: 60-Minute Lecture
Learning Objective #1: Identify the growing threat counterfeit drugs pose in our healthcare supply chain to patients with some containing no active ingredients, and others containing toxic ingredients and contaminants
Learning Objective #2: Discuss how the Drug Supply Chain Security Act (DSCSA) legislation may help ensure drug safety and improve patient care, but could also cause delays throughout the pharmaceutical supply chain
Learning Objective #3: Explain the findings of The Axia Institute’s pilot study at Michigan State University, examining track and trace technologies to combat counterfeit drugs in support of DSCSA legislation and helping mitigate logistical delays
Learning Objective #4: Describe current and emerging technology and best practice workflows that can be leveraged to increase drug safety and improve patient care from manufacture to patient administration
